RHAPSODY试验最终结果:一项多中心2期试验,采用持续重评估方法确定3K3A-APC(人活化蛋白C重组变体)联合组织型纤溶酶原激活剂、机械取栓或两者兼用于中重度急性缺血性卒中的安全性和耐受性
RHAPSODY是一项随机、对照、盲法多中心2期试验,采用持续重评估方法,在110例接受静脉溶栓、机械取栓或两者兼有的缺血性卒中患者中确定3K3A-APC的最大耐受剂量。最大耐受剂量为540 μg/kg,估计毒性率为7%。预设脑出血率无差异;探索性分析显示3K3A-APC联合治疗组脑出血率较安慰剂降低(86.5% vs 67.4%,p=0.046),总出血体积有降低趋势(p=0.066),需确认。
要点
- RHAPSODY试验确定3K3A-APC在缺血性卒中患者中的最大耐受剂量为540 μg/kg,估计毒性率7%。
- 预设脑出血率在3K3A-APC与安慰剂间无差异。
- 探索性分析中3K3A-APC联合治疗组脑出血率较安慰剂降低(86.5% vs 67.4%,p=0.046),需确认。
核心结论
- RHAPSODY是首个在允许取栓、溶栓或两者兼有的试验设计中测试急性缺血性卒中神经保护剂的试验。
- PAR1活性细胞保护剂3K3A-APC的最大耐受剂量为540 μg/kg。
- 探索性分析中出血率降低的趋势需要确认。
研究设计与样本
- 随机、对照、盲法多中心2期试验,采用持续重评估方法确定最大耐受剂量。
- 2015年1月至2017年7月共治疗110例患者, demographics与典型卒中人群相似。
- 剂量组为120、240、360和540 μg/kg的3K3A-APC或安慰剂,在静脉组织型纤溶酶原激活剂、动脉内机械取栓或两者之后给药。
主要发现
- 最大耐受剂量为最高测试剂量540 μg/kg,估计毒性率为7%。
- 预设脑出血率无差异。
- 探索性分析中,3K3A-APC联合治疗组脑出血率较安慰剂从86.5%降至67.4%(p=0.046)。
- 探索性分析中,总出血体积安慰剂组平均2.1 ± 5.8 ml,联合治疗组平均0.8 ± 2.1 ml(p=0.066)。
关键数值与推荐
- 最大耐受剂量为540 μg/kg,估计毒性率7%。
- 探索性分析脑出血率:联合治疗组67.4% vs 安慰剂组86.5%(p=0.046)。
- 探索性分析总出血体积:联合治疗组平均0.8 ± 2.1 ml vs 安慰剂组平均2.1 ± 5.8 ml(p=0.066)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 探索性分析中出血率降低的趋势需要确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Agonism of protease-activated receptor (PAR) 1 by activated protein C (APC) provides neuro- and vasculoprotection in experimental neuroinjury models. The pleiotropic PAR1 agonist, 3K3A-APC, reduces neurological injury and promotes vascular integrity; 3K3A-APC proved safe in human volunteers. We performed a randomized, controlled, blinded trial to determine the maximally tolerated dose (MTD) of 3K3A-APC in ischemic stroke patients. METHODS: The NeuroNEXT trial, RHAPSODY, used a novel continual reassessment method to determine the MTD using tiers of 120, 240, 360, and 540 μg/kg of 3K3A-APC. After intravenous tissue plasminogen activator, intra-arterial mechanical thrombectomy, or both, patients were randomized to 1 of the 4 doses or placebo. Vasculoprotection was assessed as microbleed and intracranial hemorrhage (ICH) rates. RESULTS: Between January 2015 and July 2017, we treated 110 patients. Demographics resembled a typical stroke population. The MTD was the highest-dose 3K3A-APC tested, 540 μg/kg, with an estimated toxicity rate of 7%. There was no difference in prespecified ICH rates. In exploratory analyses, 3K3A-APC reduced ICH rates compared to placebo from 86.5% to 67.4% in the combined treatment arms (p = 0.046) and total hemorrhage volume from an average of 2.1 ± 5.8 ml in placebo to 0.8 ± 2.1 ml in the combined treatment arms (p = 0.066). INTERPRETATION: RHAPSODY is the first trial of a neuroprotectant for acute ischemic stroke in a trial design allowing thrombectomy, thrombolysis, or both. The MTD was 540 μg/kg for the PAR1 active cytoprotectant, 3K3A-APC. A trend toward lower hemorrhage rate in an exploratory analysis requires confirmation. CLINICAL TRIAL REGISTRATION: Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT02222714. ANN NEUROL 2019;85:125-136.
引用
- Lyden P, Pryor KE, Coffey CS, et al. Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke. Ann Neurol. 2019. PMID: 30450637. doi:10.1002/ana.25383
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。